Trial Profile
A study evaluating efficacy of chemotherapy given after immune checkpoint inhibitor therapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Bevacizumab; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed; Ramucirumab; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology